Results 151 to 160 of about 14,850 (194)

Impact of dapagliflozin on bone mineral metabolism in non-diabetic patients with chronic kidney disease: a randomized, double-blind, placebo-controlled study. [PDF]

Clin Kidney J
Elshayeb M, Abdulgalil A, El-Husseini A, Elhadedy M, Sally S, Refaie H, Mortada W, Nabieh K, Sobh M.   +8 more
europepmc   +1 more source

Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study. [PDF]

Sci Rep
Kim K, Ko SH, Yun JS, Lee KW, Kim ES, Jeong IK, Kim JH, Kim SY, Won KC, Kim M, Cha BS, Kim S, Choi SH, Rhee EJ, Kim SG, Kim BH, Park KS, Ju YC, Heo TW, Ahn YB.   +19 more
europepmc   +1 more source

Dapaglifozin use in pediatric IgA nephropathy: a single-center real-life experience. [PDF]

Clin Kidney J
Petruzzelli LA, Malgieri G, Carucci M, De Marco O.   +3 more
europepmc   +1 more source

Dapagliflozin treatment ameliorates oxidative stress, apoptosis and inflammation in tenofovir-induced nephrotoxicity in rats. [PDF]

Sci Rep
Dos Santos VA, Viotto ACR, Nascimento MM, Bernardo DRD, Shimizu MHM, de Sena CR, Seguro AC, Volpini RA, de Bragança AC, Canale D.   +9 more
europepmc   +1 more source

Triple arm, prospective, real-world study comparing the efficacy of FDC teneligliptin + dapagliflozin to FDC sitagliptin + dapagliflozin, and FDC linagliptin + empagliflozin in Indian type 2 diabetes mellitus patients using CGM device: the Amplify-TIR study. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Erande S, Agrawal M, Gulati S, Jagtap N, Kumar NSP, Kapoor VK, Bhushan S, Gadkari R, Jadhav M, Choudhari S, Patil S, Barkate H.   +11 more
europepmc   +1 more source

Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD). [PDF]

BMJ Open
Zhang W, Dou Y, Liu J, Liu T, Yan W, Shen Q, Xu H, Zhai Y.   +7 more
europepmc   +1 more source

Effect of SGLT2 inhibitors on heart failure outcomes in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Exp Ther Med
Bafail DA, Alhalees NH.
europepmc   +1 more source

Multiscale computational analysis reveals enhanced allosteric modulation of Nav1.5 by dual binding of dapagliflozin and ertugliflozin. [PDF]

Sci Rep
Chattopadhyay A, Fatehi M, Mosa FES, Gruber B, Light PE, Barakat K.   +5 more
europepmc   +1 more source